Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes

Addiction Biology

Volumn 19, Issue 6, 2014, Pages 1006-1019

  O'Dell, Laura E ^a   Natividad, Luis A ^a   Pipkin, Joseph A ^a   Roman, Francisco ^a   Torres, Ivan ^a   Jurado, Jesus ^a   Torres, Oscar V ^a   Friedman, Theodore C ^b   Tenayuca, John M ^c   Nazarian, Arbi ^c  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b DREW UNIVERSITY   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Abuse; diabetes; dopamine; hyperglycemia; hypoinsulinemia; self administration; tobacco

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; NICOTINE; STREPTOZOCIN; GLUCOSE BLOOD LEVEL; NICOTINIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOPAMINERGIC SYSTEM; DRUG METABOLISM; DRUG SELF ADMINISTRATION; FLUID INTAKE; FOOD INTAKE; INTRAVENOUS SELF ADMINISTRATION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PROTEIN ANALYSIS; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; INSTRUMENTAL CONDITIONING; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; REINFORCEMENT; REWARD; WISTAR RAT;

ANIMALS; BLOOD GLUCOSE; CONDITIONING, OPERANT; DIABETES MELLITUS, EXPERIMENTAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRAVENOUS; MALE; NICOTINE; NICOTINIC AGONISTS; NUCLEUS ACCUMBENS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); REWARD; SELF ADMINISTRATION;

EID: 84916231385     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12074     Document Type: Article

References (68)

1. Afonso-Oramas D, Cruz-Muros I, Alvarez de la Rosa D, Abreu P, Giraldez T, Castro-Hernandez J, Salas-Hernandez J, Lanciego JL, Rodriguez M, Gonzalez-Hernandez T, (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease. Neurobiol Dis 36: 494-508.
2. Aiyar N, Baker E, Martin J, Patel A, Stadel JM, Willette RN, Barone FC, (1995) Differential calcitonin gene-related peptide (CGRP) and amylin binding sites in nucleus accumbens and lung: potential models for studying CGRP/amylin receptor subtypes. J Neurochem 65: 1131-1138.
3. Artinano A, Castro M, (2009) Experimental rat models to study the metabolic syndrome. Br J Nutr 102: 1246-1253.
4. Aston-Jones G, Harris GC, (2004) Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 47 (Suppl 1): 167-179.
5. Bell RH, Jr, Hye RJ, (1983) Animal models of diabetes mellitus: physiology and pathology. J Surg Res 35: 433-460.
6. Berman Y, Devi L, Spangler R, Kreek MJ, Carr KD, (1997) Chronic food restriction and streptozotocin-induced diabetes differentially alter prodynorphin mRNA levels in rat brain regions. Brain Res Mol Brain Res 46: 25-30.
7. Bishop FK, Maahs DM, Snell-Bergeon JK, Ogden LG, Kinney GL, Rewers M, (2009) Lifestyle risk factors for atherosclerosis in adults with type 1 diabetes. Diab Vasc Dis Res 6: 269-275.
8. Briese E, Hernández L, (1970) Self-stimulation enhancement in diabetic rats. Acta Physiol Lat Am 20: 24-29.
9. Bromocriptine (Cycloset) for type 2 diabetes (2010) Med Lett Drugs Ther 52: 97-98.
10. Carelli RM, Wightman RM, (2004) Functional microcircuitry in the accumbens underlying drug addiction: insights from real-time signaling during behavior. Curr Opin Neurobiol 14: 763-768.
11. Carr KD, (1994) Streptozotocin-induced diabetes produces a naltrexone-reversible lowering of self-stimulation threshold. Brain Res 664: 211-214.
12. Carr KD, Kim G, Cabeza de Vaca S, (2000) Hypoinsulinemia may mediate the lowering of self-stimulation thresholds by food restriction and streptozotocin-induced diabetes. Brain Res 863: 160-168.
13. Christopoulos G, Paxinos G, Huang XF, Beaumont K, Toga AW, Sexton PM, (1995) Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 73: 1037-1041.
14. Corrigall WA, Coen KM, (1989) Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 99: 473-478.
15. Corrigall WA, Coen KM, (1991) Selective dopamine antagonists reduce nicotine self-administration. Psychopharmacology (Berl) 104: 171-176.
16. Corrigall WA, Franklin KB, Coen KM, Clarke PB, (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 107: 285-289.
17. Dagher A, Bleicher C, Aston JA, Gunn RN, Clarke PB, Cumming P, (2001) Reduced dopamine D1 receptor binding in the ventral striatum of cigarette smokers. Synapse 42: 48-53.
18. Eliasson B, Attvall S, Taskinen MR, Smith U, (1997) Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 27: 450-456.
19. Figlewicz DP, Bennett J, Evans SB, Kaiyala K, Sipols AJ, Benoit SC, (2004) Intraventricular insulin and leptin reverse place preference conditioned with high-fat diet in rats. Behav Neurosci 118: 479-487.
20. Figlewicz DP, Bennett JL, Aliakbari S, Zavosh A, Sipols AJ, (2008) Insulin acts at different CNS sites to decrease acute sucrose intake and sucrose self-administration in rats. Am J Physiol Regul Integr Comp Physiol 295: R388-R394.
21. Figlewicz DP, Bennett JL, Naleid AM, Davis C, Grimm JW, (2006) Intraventricular insulin and leptin decrease sucrose self-administration in rats. Physiol Behav 89: 611-616.
22. Figlewicz DP, Evans SB, Murphy J, Hoen M, Baskin DG, (2003) Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 964: 107-115.
23. Galici R, Galli A, Jones DJ, Sanchez TA, Saunders C, Frazer A, Gould GG, Lin RZ, France CP, (2003) Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats. Neuroendocrinology 77: 132-140.
24. Gill GV, Morgan C, MacFarlane IA, (2005) Awareness and use of smoking cessation treatments among diabetic patients. Diabet Med 22: 658-660.
25. Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, Solberg LI, (2005) Predictors of health care costs in adults with diabetes. Diabetes Care 28: 59-64.
26. Goldberg SR, Spealman RD, Goldberg DM, (1981) Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214: 573-575.
27. Harris AC, Pentel PR, Lesage MG, (2007) Prevalence, magnitude, and correlates of an extinction burst in drug-seeking behavior in rats trained to self-administer nicotine during unlimited access (23 h/day) sessions. Psychopharmacology (Berl) 194: 395-402.
28. Havrankova J, Roth J, Brownstein M, (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272: 827-829.
29. Henningfield JE, Miyasato K, Jasinski DR, (1985) Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234: 1-12.
30. Johnson KH, O'Brien TD, Hayden DW, Jordan K, Ghobrial HK, Mahoney WC, Westermark P, (1988) Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130: 1-8.
31. Könner AC, Hess S, Tovar S, Mesaros A, Sanchez-Lasheras C, Evers N, Verhagen LA, Bronneke HS, Kleinridders A, Hampel B, Kloppenburg P, Bruning JC, (2011) Role for insulin signaling in catecholaminergic neurons in control of energy homeostasis. Cell Metab 13: 720-728.
32. Laviolette SR, Lauzon NM, Bishop SF, Sun N, Tan H, (2008) Dopamine signaling through D1-like versus D2-like receptors in the nucleus accumbens core versus shell differentially modulates nicotine reward sensitivity. J Neurosci 28: 8025-8033.
33. Lee JH, Yang SH, Oh JM, Lee MG, (2010) Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol 62: 1-23.
34. LeSage MG, Keyler DE, Collins G, Pentel PR, (2003) Effects of continuous nicotine infusion on nicotine self-administration in rats: relationship between continuously infused and self-administered nicotine doses and serum concentrations. Psychopharmacology (Berl) 170: 278-286.
35. LeSage MG, Keyler DE, Shoeman D, Raphael D, Collins G, Pentel PR, (2002) Continuous nicotine infusion reduces nicotine self-administration in rats with 23-h/day access to nicotine. Pharmacol Biochem Behav 72: 279-289.
36. Lim DK, Lee KM, Ho IK, (1994) Changes in the central dopaminergic systems in the streptozotocin-induced diabetic rats. Arch Pharm Res 17: 398-404.
37. Lukinius A, Wilander E, Westermark GT, Engström U, Westermark P, (1989) Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32: 240-244.
38. Mangubat M, Lutfy K, Lee ML, Pulido L, Stout D, Davis R, Shin CS, Shahbazian M, Seasholtz S, Sinha-Hikim A, Sinha-Hikim I, O'Dell LE, Lyzlov A, Liu Y, Friedman TC, (2012) Effect of nicotine on body composition in mice. J Endocrinol 212: 317-326.
39. Mansvelder HD, De Rover M, McGehee DS, Brussaard AB, (2003) Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharmacol 480: 117-123.
40. Masiello P, (2006) Animal models of type 2 diabetes with reduced pancreatic beta-cell mass. Int J Biochem Cell Biol 38: 873-893.
41. Morrow TJ, (2004) Animal models of painful diabetic neuropathy: the STZ rat model. Curr Protoc Neurosci Chapter 9: Unit 9.18.
42. Murzi E, Contreras Q, Teneud L, Valecillos B, Parada MA, De Parada MP, Hernandez L, (1996) Diabetes decreases limbic extracellular dopamine in rats. Neurosci Lett 202: 141-144.
43. O'Dell LE, Chen SA, Smith RT, Specio SE, Balster RL, Paterson NE, Markou A, Zorrilla EP, Koob GF, (2007) Extended access to nicotine self-administration leads to dependence: circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther 320: 180-193.
44. O'Dell LE, Koob GF, (2007) 'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration. Pharmacol Biochem Behav 86: 346-353.
45. O'Dell LE, Parsons LH, (2004) Serotonin1B receptors in the ventral tegmental area modulate cocaine-induced increases in nucleus accumbens dopamine levels. J Pharmacol Exp Ther 311: 711-719.
46. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL, (1990) Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 85: 973-976.
47. Owens WA, Sevak RJ, Galici R, Chang X, Javors MA, Galli A, France CP, Daws LC, (2005) Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem 94: 1402-1410.
48. Owens WA, Williams JM, Saunders C, Avison MJ, Galli A, Daws LC, (2012) Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism. J Neurosci 32: 2637-2647.
49. Paxinos G, Watson C, (1998) The Rat Brain in Stereotaxic Coordinates, 4th edn. San Diego, CA: Academic Press.
50. Risner ME, Goldberg SR, (1983) A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J Pharmacol Exp Ther 224: 319-326.
51. van Rossum D, Ménard DP, Fournier A, St-Pierre S, Quirion R, (1994) Autoradiographic distribution and receptor binding profile of [125I]Bolton Hunter-rat amylin binding sites in the rat brain. J Pharmacol Exp Ther 270: 779-787.
52. Saitoh A, Morita K, Sodeyama M, Kamei J, (1998) Effects of the experimental diabetes on dopamine D1 receptor-mediated locomotor-enhancing activity in mice. Pharmacol Biochem Behav 60: 161-166.
53. Salkovic M, Sabolic I, Lackovic Z, (1995) Striatal dopaminergic D1 and D2 receptors after intracerebroventricular application of alloxan and streptozocin in rat. J Neural Transm Gen Sect 100: 137-145.
54. Saller CF, (1984) Dopaminergic activity is reduced in diabetic rats. Neurosci Lett 49: 301-306.
55. Saller CF, Chiodo LA, (1980) Glucose suppresses basal firing and haloperidol-induced increases in the firing rate of central dopaminergic neurons. Science 210: 1269-1271.
56. Scemama O, Hamo-Tchatchouang E, Le Faou AL, Altman JJ, (2006) Difficulties of smoking cessation in diabetic inpatients benefiting from a systematic consultation to help them to give up smoking. Diabetes Metab 32: 435-441.
57. Scott JN, Clark AW, Zochodne DW, (1999) Neurofilament and tubulin gene expression in progressive experimental diabetes: failure of synthesis and export by sensory neurons. Brain 122 (Pt 11): 2109-2118.
58. Sevak RJ, Koek W, Daws LC, Owens WA, Galli A, France CP, (2008) Behavioral effects of amphetamine in streptozotocin-treated rats. Eur J Pharmacol 581: 105-112.
59. Sevak RJ, Koek W, France CP, (2005) Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy. Eur J Pharmacol 517: 64-67.
60. Sevak RJ, Owens WA, Koek W, Galli A, Daws LC, France CP, (2007) Evidence for D2 receptor mediation of amphetamine-induced normalization of locomotion and dopamine transporter function in hypoinsulinemic rats. J Neurochem 101: 151-159.
61. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K, (1994) In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62: 553-567.
62. Sumiyoshi T, Ichikawa J, Meltzer HY, (1997) The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain. Neuropsychopharmacology 16: 183-190.
63. Tonstad S, (2009) Cigarette smoking, smoking cessation, and diabetes. Diabetes Res Clin Pract 85: 4-13.
64. Valentine JD, Hokanson JS, Matta SG, Sharp BM, (1997) Self-administration in rats allowed unlimited access to nicotine. Psychopharmacology (Berl) 133: 300-304.
65. Wei M, Ong L, Smith MT, Ross FB, Schmid K, Hoey AJ, Burstow D, Brown L, (2003) The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ 12: 44-50.
66. Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, France CP, Gore JC, Daws LC, Avison MJ, Galli A, (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 5: e274.
67. Wolinsky TD, Abrahamsen GC, Carr KD, (1996) Diabetes alters mu and kappa opioid binding in rat brain regions: comparison with effects of food restriction. Brain Res 738: 167-171.
68. Yokel RA, Wise RA, (1976) Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology (Berl) 48: 311-318.